Similar Search Results

Management of HIV-1 Infection in Children: Special Considerations

Brady, Michael T. - In: Disease Management and Health Outcomes 4 (1998) 2, pp. 73-91

Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...

Persistent link: https://www.econbiz.de/10005448902

Assessing the Willingness of Parents to Pay for Reducing Postoperative Emesis in Children

Diez, Lara - In: PharmacoEconomics 13 (1998) 5, pp. 589-595

This study assessed the willingness of parents to pay for a reduction in the postoperative emesis experienced by children. The willingness-to-pay technique was used to value the intangible benefits, such as relief from anxiety and discomfort, resulting from a reduction in postoperative emesis in...

Persistent link: https://www.econbiz.de/10005449231

Anti-Inflammatory Medication Adherence, Healthcare Utilization and Expenditures among Medicaid and Children's Health Insurance Program Enrollees with Asthma

Herndon, Jill Boylston.; Mattke, Soeren; Evans Cuellar, … - In: PharmacoEconomics 30 (2012) 5, pp. 397-412

Background:Background: Underuse of controller therapy among Medicaid-enrolled children is common and leads to more emergency department (ED) visits and hospitalizations. However, there is little evidence about the relationship between medication adherence, outcomes and costs once controller...

Persistent link: https://www.econbiz.de/10010541097

Patent Extension Policy for Paediatric Indications: An Evaluation of the Impact within Three Drug Classes in a State Medicaid Programme

Nelson, Richard E.; McAdam-Marx, Carrie; Evans, Megan L.; … - In: Applied Health Economics and Health Policy 9 (2011) 3, pp. 171-181

Medicaid prescription claims obtained for statins, ACE inhibitors and SSRIs included reimbursement amount, number of units … before and 12 months after generic availability. The percentage difference between the brand name prescription reimbursement … amount to Medicaid in the last 2 months of the 6-month extension and the generic prescription reimbursement amount to …

Persistent link: https://www.econbiz.de/10010614273

Economic Impact of Respiratory Syncytial Virus-Related Illness in the US: An Analysis of National Databases

Paramore, L. Clark; Ciuryla, Vincent; Ciesla, Gabrielle; … - In: PharmacoEconomics 22 (2004) 5, pp. 275-284

Objective: To determine the impact of respiratory syncytial virus (RSV) infection on healthcare resource use and costs in the US from the third-party payer perspective. Design: The study retrospectively analysed cross-sectional medical encounter data from three federally funded databases that...

Persistent link: https://www.econbiz.de/10005449224

Household-Based Costs and Benefits of Vaccinating Healthy Children in Daycare Against Influenza Virus: Results from a Pilot Study

Pisu, Maria; Meltzer, Martin I.; Hurwitz, Eugene S.; … - In: PharmacoEconomics 23 (2005) 1, pp. 55-67

Background: Vaccinating children against influenza virus may reduce infections in immunised children and household contacts, thereby reducing the household-based cost associated with respiratory illnesses. Objective: To evaluate the impact of influenza virus vaccination of daycare children on...

Persistent link: https://www.econbiz.de/10005404931

Sickle Cell Disease Screening Programs: Integration Into Managed Care

Davies, Sally C.; Oni, Lola - In: Disease Management and Health Outcomes 9 (2001) 6, pp. 295-304

Screening programs for sickle cell disease, when effective, can reduce morbidity and mortality as a direct consequence of patient education and optimized clinical management. However, informed patient or parental consent is necessary prior to the screening process as a person's sickle status is...

Persistent link: https://www.econbiz.de/10005242993

Prevention of Recurrent Rhinopharyngitis in At-Risk Children in France: A Cost-Effectiveness Model for a Nonspecific Immunostimulating Bacterial Extract (OM-85 BV)

Pessey, Jean-Jacques; Megas, Francoise; Arnould, Benoit; … - In: PharmacoEconomics 21 (2003) 14, pp. 1053-1068

Objective: To estimate the pharmacoeconomic impact for the French Social Security System of preventing recurrent acute rhinopharyngitis (RARP) in at-risk children with OM-85 BV, an immunostimulating agent indicated for the prevention of recurrences. Design: A decision-analysis model. The...

Persistent link: https://www.econbiz.de/10005243125

The Economics of Hepatitis B Virus Vaccination: An Analysis of Cost-Effectiveness Results for Switzerland

Zurn, Pascal; Carrin, Guy; Danthine, Jean-Pierre; … - In: Disease Management and Health Outcomes 7 (2000) 6, pp. 331-347

Objective: To assess and compare the costs and effectiveness of different vaccination strategies against hepatitis B in Switzerland. Design: A birth cohort of 85 000 individuals was followed over their lifetime, using a decision-tree analysis. Published data were used to simulate the risk of...

Persistent link: https://www.econbiz.de/10005448762

Use and Cost of Hospital and Community Service Provision for Children with HIV Infection at an English HIV Referral Centre

Beck, Eduard J.; Mandalia, Sundhiya; Griffith, Rebecca; … - In: PharmacoEconomics 17 (2000) 1, pp. 53-69

Objective: To describe the use of hospital and community services for children infected with HIV and estimate the cost per patient-year by stage of HIV infection during the era of antiretroviral monotherapy. Design: Data on the use of hospital services were collected from case notes; the use of...

Persistent link: https://www.econbiz.de/10005449015

1
2
3
4
5
6
7
8
9
10
Next
Last